Telomir Pharmaceuticals, Inc. — Investor Relations & Filings

Telomir Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company focused on the development of Telomir-1, its lead product candidate. Telomir-1 is an investigational oral small molecule designed to address the cellular drivers of aging and chronic disease. Its proposed mechanism of action involves regulating intracellular metals, such as iron and copper, to interrupt enzyme function. The therapy aims to extend and protect telomeres, reset abnormal DNA methylation patterns, reduce oxidative stress, and restore mitochondrial function. By targeting these fundamental processes, the company seeks to develop treatments for age-related conditions and specific disorders like Wilson's Disease.